Phase 4
Completed N=50
A Single-Center Evaluation of the Anti-Inflammatory Effects of Lastacaft as Measured by In-Vivo Confocal Microscopy
Source: ClinicalTrials.gov NCT02308501 ↗Enrolled (actual)
50
Serious AEs
0.0%
Results posted
Mar 2021
Primary outcomePrimary: Conjunctival Inflammation at 1 Hour (+30 Minutes) Post CAC on Day 1 — 3.12; 3.02 units on a scale
◆ Published Evidence
No publication linked
No peer-reviewed publication reporting this trial's results has been linked yet. This can indicate results are unpublished — a known publication-bias signal. We re-check periodically.
Summary
A Single-Center Evaluation of the Anti-Inflammatory Effects of Lastacaft ® as Measured by In-Vivo Confocal Microscopy
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Conjunctival Inflammation at 1 Hour (+30 Minutes) Post CAC on Day 1 |
3.12; 3.02 | — |
| PRIMARY Conjunctival Inflammation 1 Hour (+30 Minutes) Post CAC on Day 2 |
2.44; 2.90 | — |
| SECONDARY Ocular Itching on Day 1 (15 Minutes Post-study Medication Instillation) |
0.72; 2.19; 0.88; 2.41; 0.91; 2.38 | — |
| SECONDARY Ocular Itching on Day 2 (15 Minutes Post-study Medication Instillation) |
0.84; 2.00; 1.16; 2.22; 1.19; 2.22 | — |
Eligibility Criteria
Inclusion Criteria
- Have a positive history of ocular allergies and a positive skin test to protocol defined allergens
- Have a positive CAC reaction at Visit 1
- Have a positive conjunctival inflammation score at Visit 1
Exclusion Criteria
- May not use disallowed medications in specified washout period
- May not have an ocular or system disease the investigator feels with impact subject safety or trial parameters
- May not have active ocular infection
Data sourced from ClinicalTrials.gov (NCT02308501). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.